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ABSTRACT 
 
The  “in vitro virus” is a molecular construct to perform 
evolutionary protein engineering. The “virion(=viral 
particle)”(mRNA-peptide fusion), is made by bonding a 
nascent protein with its coding mRNA via puromycin in a test 
tube for in vitro translation. In this work, the puromycin-linker 
was attached to mRNA using the Y-ligation, which was a 
method of two single-strands ligation at the end of a double-
stranded stem to make a stem-loop structure. This reaction 
gave a yield of about 95%. We compared the Y-ligation with 
two other ligation reactions and showed that the Y-ligation 
gave the best productivity. An efficient amplification of the in 
vitro virus with this “viral genome” was demonstrated. 
 
 
INTRODUCTION 
 
 
The Darwinian selection of proteins requires a linkage of 
phenotype with genotype. The in vitro virus is a molecular 
construct to realize such a linkage. A linkage of a nascent 
protein with its coding mRNA was made on a ribosome during 
in vitro translation via a puromycin attached to the 3' end of the 
mRNA (1,2). The in vitro virus  dramatically increased the 
library diversity and the system flexibility of the in vivo version 
such as a phage display method. In fact, various aptamers have 
been evolved starting from a random library (3,4) or a cDNA 
library (5) in this approach. 
 
In the original in vitro virus the puromycin-linker was attached 
to an mRNA by simple enzymatic ligation (1). Recently, more 
efficient methods were developed such as an improved splint 
ligation method using T4 DNA ligase (6) and a photo-cross-
linked ligation method using psoralen (7). 
 
We developed a novel puromycin-linker attachment technology 
using the Y-ligation, which was a method of two single-strands 
ligation at the end of a double-stranded stem to make a stem-
loop structure. The Y-ligation method (8) gave a high yield by 
increasing the local effective concentration of the two 
oligodeoxyribonucleotides and by using T4 RNA ligase. We 
applied this method in preparation of the “genome” of an in 
vitro virus and demonstrated a high yield in the “virion (=viral 
particle)” (mRNA-peptide fusion) formation of the in vitro 
virus and its amplification. 
 
 
MATERIALS AND METHODS 
 
Synthesis of DNA-oligomer with Puromycin-
linker 
 
Puromycin-linkers (Fig. 1) were synthesized by using a 
standard DNA synthetic method and purified in the reverse Tabuchi et al.    
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phase HPLC. Puromycin-CPG and phosphoramidites were 
purchased from Glen Research and used according to the 
protocols recommended by the manufacturer. The sequences of 
linker-S, linker-Y and splint DNA were (A)12-(Spacer18)2-
d(CC)-Puromycin, d(CCC)-(GCCCCCCGTCCC)OMe-
(Spacer18)4-(CC)OMe-Puromycin and d((T)9GCCCCCC-
GTCCC), respectively. Here, Spacer18 is -(OCH2CH2)6PO2O-. 
The 5’ end of puromycin-linkers was phosphorylated using T4 
polynucleotide kinase (NEB). The base sequences of 3’ end 
region (a GC clump) of mRNA were 
5’….GGGACGGGGGGC3’ and 5’….GGGAC-
GGGGGGCAAAA3’ for the splint ligation and the Y-ligation, 
respectively. 
 
 
Fig. 1: Scheme of ligation methods of puromycin-linker to 
mRNA. P and F denote Puromycin and FITC, respectively. 
The sequence of “Y-ligation loop” is d(CCC) 5’ and r(AAAA) 
3’. 
 
Ligation reaction 
 
DNA “genomes” were prepared by PCR with different primer 
sets in two steps using the plasmid pETHisKGFP as an initial 
template. The plasmid pETHisKGFP was constructed by 
inserting the GFP gene of phGFPS65T (Clontech) into the 
pETHisK vector (9). The construct of genome has a T7 
promoter, a translational enhancer of TMV 5' UTR (10), an 
initiation codon with good context (11), a coding sequence of 
His-tag (12), an N-terminus sequence in the GFP gene and a 
GC-clump sequence for hybridization to a GC-rich DNA-
oligomer. The PCR primers and the mRNA sequence are the 
same as described in (13). Capped mRNAs were prepared 
using the DNA genomes and T7 RNA polymerase transcription 
kit (RiboMAX-T7; Promega). 
 
Messenger RNAs (0.5 µM) were hybridized with each linker 
with or without a splint DNA in an annealing condition of 15 
min / from-94-to-25 ºC in each ligation buffers. The ligation 
reaction with T4 DNA ligase (10 U/µl, NEB) was performed 
according to the supplier's recommendation at 25 ºC. The 
ligation reaction with T4 RNA ligase (1 U/µl, TAKARA) was 
performed in the supplier's buffer with 10% DMSO at 25 ºC. 
The ligation products were analyzed by 8 M urea 10% PAGE 
using TBE running buffer at 65 ºC and were visualized with 
fluorescence of FITC and then visualized again after staining 
by SYBR Green II (FMC) using an fluorescence imager 
(Molecular Imager FX; BIO-RAD). Splint ligation products 
were then treated with T7 exonuclease, at 37 ºC 15 min, in 
order to digest the DNA splint and were purified by a spin 
column (S-200HR; Amersham Pharmacia). 
 
Analysis of formation of in vitro virion 
 
The mRNAs were translated in wheat-germ extract 
(TOYOBO) for 15 min at 25 ºC in standard condition and for 
30 min at 10 ºC in a high salt condition (final 50 mM MgCl2, 
500 mM KCl). The products were analyzed using 6 M urea 
10% SDS-Tricin PAGE (14) and visualized using the 
fluorescence imager. 
 
Affinity columns of Ni-NTA agarose (QIAGEN; 200µl gel 
volume (Vc)) were used. The virion (mRNA-peptide fusion) 
was diluted in a TBS buffer (50 mM Tris-HCl, 150mM NaCl, 
0.1% Tween20, pH 8.0) and incubated in each affinity column 
for 5 min at 25 ºC. The Ni-NTA agarose column was washed 
with 25 Vc of a buffer (50 mM Tris-HCl, 1 M NaCl, 0.1% 
Tween20, 10 mM imidazole, pH 8.0) and eluted with 2.5 Vc of 
a buffer (50 mM Tris-HCl, 0.1% Tween20, 500mM imidazole, 
pH 8.0). Eluted solution was desalted by P6 spin column (Bio-
rad). Reverse transcription was performed using 
C.therm.Polymerase (Roche) for 30 min at 65 ºC. A PCR was 
performed (25 cycles) using KOD Dash polymerase 
(TOYOBO) and analyzed by electrophoresis on 3% agarose gel 
(MetaPhor agarose; FMC) using triethanolamine / Tricin 
running buffer (15) and were visualized using the imager. 
 
RESULTS AND DISCUSSION 
 
Ligation reaction between mRNA and 
puromycin-linker 
 
We compared three puromycin-linker attachment methods, 
which are the splint ligation with T4 DNA ligase (6), the splint 
ligation with T4 RNA ligase and the Y-ligation with T4 RNA 
ligase (Fig. 1). 
 
The splint ligation method with T4 DNA ligase gave a low 
product yield because of undesirable mRNA terminal 
heterogeneity originated from the T7 run-off transcription (6). 
This drawback was overcome by an improved splint ligation 
with a T4 DNA ligase (6). Two kinds of splint “N” and “N+1” 
were used in the improved method. 
 
We tested another method against mRNA terminal 
heterogeneity, which was splint ligation with T4 RNA ligase. 
T4 RNA ligase can ligate nucleotides even if the 3’ end of 
mRNA is not a complementary double strand. Thus, it is 
expected that mRNA with an N+1 terminus can ligate while 
total ligation yield increases. 
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Both splint ligations gave a relatively high yield of the ligation 
products. But the removal of the splint by PAGE (6) was 
troublesome. We removed the splint by treatment with T7 
exonuclease. This removal method was rapid and efficient. 
However, some leftover splint DNAs inhibited the virion 
formation (7) and cleaved mRNA by RNaseH during 
translation (16). 
 
We developed a puromycin-linker ligation method, using the 
Y-ligation. This method was simpler and did not require 
removing the splint DNA. We optimized reaction conditions of 
each method, that is, reaction buffers, temperature, molar ratios 
of [mRNA]:[splint]:[Linker-S], etc. Comparisons of the results 
of the three puromycin-linker attachment methods are shown in 
Fig. 2. The DNA ligase method gave a low yield. The RNA 
ligase method gave a yield of about 60%. The Y-ligation 
method had the best result and gave a yield of about 95%. It 
was reported that the improved splint ligation method using T4 
DNA ligase and the photo-cross-linked ligation method using 
psoralen gave a yield of more than 70% (6) and exceeding 80% 
(7), respectively. The photo-cross-linked ligation method 
includes a process of a long time (15min) UV irradiation (7). 
This might make mRNA damaged. And some mismatched 
linkers might be also ligated. Y-ligation method does not have 
such problems. 
 
 
Fig. 2: Gel-electrophoresis of ligation products. The ligation 
products were electrophoresed on 8M Urea 10% PAGE at 65 
ºC and were visualized with fluorescence of FITC and then 
visualized after staining by SYBR Green II using an imager. 
Lane CY: control, Linker-Y. Lane CS: control, mRNA without 
ligation. Lane CR: control, Linker-S. Lane Y: Y-ligation with 
T4 RNA ligase. Lane R: splint ligation with T4 RNA ligase. 
Lane D: splint ligation with T4 DNA ligase. 
 
We also found that the dependence of the ligation efficiency on 
mRNA length was negligible up to 800 bases (data not shown). 
Time-courses of puromycin-linker attachment reactions are 
shown in Fig. 3. The Y-ligation reaction was very fast. Most of 
the templates were already ligated in five minutes incubation. 
The splint ligation reaction was slower, because the rate of the 
mRNA-splint-linker formation may be relatively low. 
 
The dependence of the ligation efficiency on the molar ratio 
[mRNA]:[Linker-Y] is shown in Fig. 4. The Y-ligation 
reaction proceeded with a high efficiency, even in a 1:1 ratio. 
Moreover, the removal of excess linkers was not necessary. 
 
 
Fig. 3: Time course of ligation reactions. Concentrations were 
[mRNA] = 0.5 µM and [T4 RNA ligase] = 1 U/µl in the 
enzyme-supplier’s buffer with 10% DMSO. At 25 ºC. 
(a) Y-ligation, [mRNA]:[Linker-Y] = 1:1.5 
(b) Splint ligation with T4 RNA ligase as compared with Y-
ligation, [mRNA]:[Splint]:[Linker-S] = 1:1:1.5 
 
 
Fig. 4: The dependence of the Y-ligation efficiency on the 
molar ratio, [Linker-Y]/ [mRNA]. Concentration of mRNA 
was [mRNA] = 0.5 µM. The ligation efficiency is defined as 
the final fraction (at incubation time 3,600s) of the ligation 
product. 
 
 
Analysis of the formation of in vitro virion 
 
We analyzed the virion formation of the genome that was 
prepared with the Y-ligation puromycin-linker attachment Tabuchi et al.    
 
 
Biological Procedures Online • Vol. 4 No. 1 • October 28, 2002 • www.biologicalprocedures.com 
52
method. The translation reaction was performed in a wheat-
germ extract. The virion formation was detected by the 
fluorescence of the FITC labeled linker. The electrophoretic 
patterns showed the virion formation of about 40% (Fig. 5). 
This value was as high as those using a rabbit reticulocyte 
lysate for genomes prepared by other methods (6,16). 
 
 
Fig. 5: Virion formation of mRNA·Linker-Y using the Y-
ligation.Lane C: control, mRNA·Linker-Y without translation. 
Lane F: translation product. Lane D: digested translation 
product by proteinase K. 
 
As a model system for demonstrating a selection process, a 
virion having a His-tag coding region was used. In vitro virus 
virion (mRNA-peptide fusion) was made and screened through 
a Ni-NTA-immobilized affinity column. Bound virion 
(mRNA-peptide fusion) molecules were eluted and their RNA 
moiety was amplified and analyzed. Two constructs with each 
type of the puromycin-linkers and a control without translation 
were examined. During a single turnover of the life cycle of the 
in vitro virus, both puromycin-linkers amplified the viral 
genomes (and also the virions (mRNA-peptide fusions)) well, 
and the genome prepared by the Y-ligation showed higher 
amplification than the genome prepared by the splint ligation 
(Fig. 6). The linker-S had a less flexible oligonucleotide moiety 
for splint ligation. As the Y-ligation genome has a more 
flexible linker, puromycin was probably able to approach the 
ribosome A-site efficiently. The amplification for the genome 
by the splint ligation was probably lowered also by residual 
splint DNA. 
 
 
Fig. 6: PCR products from the virions after single turn-over of 
viral life cycle that had a step of the affinity trapping. In the 
reverse transcription on the virion, we used a primer (21mer) 
hybridizing at 12 bases downstream from the hybridization site 
of the Linker-Y or -S. The PCR products of the cDNAs (168-
mer both) were electrophoresed on 3% agarose gel, stained 
with ethidium bromide and visualized using the fluorescence 
imager. Lane M: 100 bp DNA ladder. Lane Y: using a genome 
with the Linker-Y. Lane S: using a genome with the Linker-S. 
Lane C: control, mRNA-Linker-Y without translation. 
 
Is there any potential biohazard in the in vitro virus? In the 
present, the in vitro virus can amplify only under the very 
limited conditions and has not any potential of infection. The 
term “virus” in in vitro virus was coined based on the 
biophysical aspect of its evolution mechanism; in the 
biotechnological aspect, this is an mRNA-peptide fusion. 
 
 
CONCLUSIONS 
 
We compared three puromycin-linker attachment methods and 
concluded that the Y-ligation method gave the best 
productivity. The Y-ligation method is an easy process because 
any after-treatments such as removal of the splint DNA are not 
necessary. We demonstrated efficient amplification of the in 
vitro virus with this “genome.” This method is also applied to 
the  in vitro DNA virus [13], when higher stability of the 
linkage between mRNA and the primer-linker is required. 
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PROTOCOLS 
 
Y-ligation to make in vitro virus 
 
1.  Hybridize the mRNA (0.5 µM) with Linker-Y (0.6µM) in an annealing condition of 15 min / from-94-to-25 ºC in ligation 
buffers. 
2.  Ligate the mRNA with the hybridized Linker-Y using T4 RNA ligase (1 U/µl, TAKARA) in the supplier's buffer with 
10% DMSO for 15 min at 25 ºC. 
3.  Analysis of the ligation products by 8 M urea 10% PAGE using TBE running buffer at 65 ºC. 
4.  Check the FITC fluorescent gel bands using a fluorescence imager (Molecular Imager FX; BIO-RAD), and then check 
again after staining by SYBR Green II (FMC). 
5.  Translate the mRNA in wheat-germ extract (TOYOBO) for 15 min at 25 ºC. And, for 30 min at 10 ºC in a high salt 
condition (final 50 mM MgCl2, 500 mM KCl). 
6.  Analysis the products using 6 M urea 10% SDS-Tricin PAGE and using the fluorescence imager. 
7.  After dilution of the virion (mRNA-peptide fusion) in a TBS buffer (50 mM Tris-HCl, 150mM NaCl, 0.1% Tween20, pH 
8.0), incubate it in affinity column (Ni-NTA agarose; QIAGEN; 200 µl gel volume (Vc)) for 5 min at 25 ºC. 
8.  Wash the column with 25 Vc of buffer (50 mM Tris-HCl, 1 M NaCl, 0.1% Tween20, 10 mM imidazole, pH 8.0). 
9.  Elution with 2.5 Vc of buffer (50 mM Tris-HCl, 0.1% Tween20, 500mM imidazole, pH 8.0). 
10.  Eluted solution was desalted by P6 spin column (Bio-rad). 
11.  Reverse transcription using C.therm.Polymerase (Roche) for 30 min at 65 ºC. 
12.  PCR (25 cycles) the RT product using KOD Dash polymerase (TOYOBO). Electrophoresis on 3% agarose gel (MetaPhor 
agarose; FMC) using tri-ethanolamine/ Tricin running buffer and visualization using an imager. 